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Background 
Streptococcus pneumoniae is a Gram-positive 
diplococcus with a well formed capsule that is 
commonly found in the nose and throat. The 
bacteria can sometimes cause severe illness in 
children, the elderly and other people with 
weakened immune systems. Streptococcus 
pneumoniae is the most common cause of middle 
ear infections, sepsis in children and pneumonia in 
immunocompromised individuals and the elderly.  
 
The Infectious Disease Epidemiology Program of 
the Maine Center for Disease Control and 
Prevention (Maine CDC) monitors the incidence of 
invasive pneumococcal disease through mandatory 
reporting by health care providers, clinical 
laboratories and other public health partners.  
Methods 
Invasive pneumococcal disease is defined as 
isolation of Streptococcus pneumoniae from a 
normally sterile site (e.g., blood or cerebrospinal 
fluid [CSF] or, less commonly, joint, pleural, or 
pericardial fluid). Antibiotic-resistant invasive 
pneumococcal disease meets the invasive 
definition and is resistant to at least one antibiotic. 
Standardized case reports are completed for all 
invasive cases, including those that are antibiotic 
resistant.   
Results 
A total of 102 cases of invasive pneumococcal 
disease were reported in Maine during 2012, for a 
rate of 7.7 cases per 100,000 persons. Of these, 79 
(77.4%) were sensitive to all antibiotics tested. 
Three invasive pneumococcal cases were in 
children less than five years.  The rate of invasive 
pneumococcal disease in children less than five 
years was 4.2 cases per 100,000 persons. Of 
cases in children less than five years, 66.7% had 
received the pneumococcal vaccine.   
 
Twenty cases of antibiotic-resistant invasive 
pneumococcal disease were reported in Maine  
 
 
 
during 2012 for a rate of 1.5 cases per 100,000 
persons (Figure 1). Of antibiotic-resistant invasive 
pneumococcal disease reported in 2012, no cases 
were identified in children less than five years of 
age (Table 1).   
 
 
 
Table 1:  Invasive and antibiotic-resistant 
pneumococcal disease by age – Maine, 2012 
Age All Invasive  Antibiotic-Resistant  
Years # # % 
<1 1 0 0 
1-4 2 0 0 
5-9 0 0 0 
10-19 1 1 5.0 
20-29 3 1 5.0 
30-39 5 3 15.0 
40-49 10 2 10.0 
50-64 23 3 15.0 
>=65 57 10         50.0 
Total 102 20 19.6 
 
The majority of cases of antibiotic-resistant invasive 
pneumococcal disease were clinically diagnosed 
with pneumonia (Table 2). Of the 20 antibiotic- 
resistant cases, there were two deaths.  
 
Table 2: Invasive pneumococcal disease by site of 
infection* – Maine, 2012 
Site of infection # % 
Bacteremia without focus 15 20 
Meningitis 5 5.5 
Pneumonia 75 44.6 
* Cases may have had more than one site of infection 
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Figure 1: Rate of antibiotic-resistant 
pneumococcal disease--Maine 2008-12 
             Prepared by Ann Farmer MS 
www.mainepublichealth.gov 
Antibiotic-resistant invasive pneumococcal disease 
was identified among residents of 11 Maine 
counties in 2012 .   
 
Figure 2: Invasive pneumococcal disease by county- 
Maine, 2012 
 
Discussion 
Maine CDC conducts routine surveillance on all 
invasive pneumococcal cases. Changes in federal 
CDC’s pneumococcal disease reporting led to 
modifications in Maine’s surveillance in 2010.   
 
Health care providers are encouraged to promote 
the use of pneumococcal vaccines. Pneumococcal 
conjugate vaccine (PCV13) is approved for all 
infants and children younger than five years of age.  
It protects against the 13 types of pneumococcal 
bacteria most likely to cause disease in infants and 
young children.  
 
All adults 65 years and older as well as persons 
with certain health conditions are encouraged to 
receive the polysaccharide pneumococcal vaccine 
(PPV23) that provides protection against 23 
serotypes of pneumococcal infection.  
 
The following persons are encouraged to receive 
PPV23: 
• Anyone 2 years of age or older with long 
term health problems such as diabetes, 
leaks of cerebrospinal fluid; heart, lung ( not 
including asthma) kidney, or liver disease; 
or alcoholism 
• Smokers older than 19 
• Adults 19 and older who have asthma 
• People who live in nursing homes or other 
long-term care facilities   
 
Invasive pneumococcal disease should be reported 
to Maine CDC by calling 1-800-821-5821 or faxing 
to 1-800-293-7534. For more information contact 
your healthcare provider or local health center.   
 
Additional information about invasive 
pneumococcal disease can be found at: 
• Maine CDC 
http://www.mainepublichealth.gov  
• Federal CDC 
http://www.cdc.gov/vaccines/vpd-
vac/pneumo/default.htm 
 
 
 
